Simulations Plus (NASDAQ:SLP) released its earnings results on Sunday. The technology company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a net margin of 22.96% and a return on equity of 24.44%.
SLP stock traded down $7.63 during midday trading on Tuesday, reaching $71.70. The company had a trading volume of 21,495 shares, compared to its average volume of 287,831. The firm has a market capitalization of $1.43 billion, a PE ratio of 152.38, a P/E/G ratio of 7.63 and a beta of -0.17. The stock has a 50 day moving average price of $65.06 and a 200 day moving average price of $65.43. Simulations Plus has a fifty-two week low of $26.00 and a fifty-two week high of $83.78.
SLP has been the subject of a number of research reports. TheStreet raised shares of Simulations Plus from a “c+” rating to a “b” rating in a research report on Friday. Raymond James started coverage on shares of Simulations Plus in a research note on Friday, October 16th. They issued an “outperform” rating and a $95.00 price target on the stock. BidaskClub upgraded Simulations Plus from a “hold” rating to a “buy” rating in a research report on Wednesday, December 23rd. Zacks Investment Research lowered Simulations Plus from a “hold” rating to a “sell” rating in a research note on Thursday, November 19th. Finally, Oppenheimer increased their price objective on shares of Simulations Plus from $79.00 to $85.00 in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Simulations Plus has an average rating of “Hold” and an average target price of $81.60.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
Further Reading: Limitations to arbitrage trading
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.